237 related articles for article (PubMed ID: 34387129)
1. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review.
Oğuz SH; Ünlütürk U; Aksoy S; Erbas T
Immunotherapy; 2021 Oct; 13(14):1157-1163. PubMed ID: 34387129
[TBL] [Abstract][Full Text] [Related]
2. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
3. Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report.
Tanaka S; Kushimoto M; Nishizawa T; Takubo M; Mitsuke K; Ikeda J; Fujishiro M; Ogawa K; Tsujino I; Suzuki Y; Abe M
Clin Diabetes Endocrinol; 2020; 6():1. PubMed ID: 31921440
[TBL] [Abstract][Full Text] [Related]
4. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
[TBL] [Abstract][Full Text] [Related]
5. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
6. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
[TBL] [Abstract][Full Text] [Related]
8. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
[TBL] [Abstract][Full Text] [Related]
10. Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists.
Druce I; Tawagi K; Shaw JLV; Ibrahim A; Lochnan H; Ong M
Curr Oncol; 2022 Jul; 29(7):4665-4677. PubMed ID: 35877230
[TBL] [Abstract][Full Text] [Related]
11. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.
Faje A; Reynolds K; Zubiri L; Lawrence D; Cohen JV; Sullivan RJ; Nachtigall L; Tritos N
Eur J Endocrinol; 2019 Sep; 181(3):211-219. PubMed ID: 31176301
[TBL] [Abstract][Full Text] [Related]
12. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis.
Bando H; Yamamoto M; Urai S; Motomura Y; Sasaki Y; Ohmachi Y; Kobatake M; Tsujimoto Y; Oi-Yo Y; Suzuki M; Yamamoto N; Takahashi M; Fukuoka H; Iguchi G; Ogawa W
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38418395
[TBL] [Abstract][Full Text] [Related]
13. Exploring a New Entity of Single-Agent Pembrolizumab-Associated Hypophysitis.
Balti E; Verhaeghe S; Kruse V; Roels S; Coremans P
Cureus; 2022 Aug; 14(8):e27763. PubMed ID: 36127991
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab-Induced Hypophysitis With Isolated Adrenocorticotropic Hormone (ACTH) Deficiency: A Rare Immune-Mediated Adverse Event.
Doodnauth AV; Klar M; Mulatu YS; Malik ZR; Patel KH; McFarlane SI
Cureus; 2021 Jun; 13(6):e15465. PubMed ID: 34123679
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.
Kotwal A; Rouleau SG; Dasari S; Kottschade L; Ryder M; Kudva YC; Markovic S; Erickson D
J Investig Med; 2022 Apr; 70(4):939-946. PubMed ID: 34969937
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features.
Esteves-Ferreira S; Rosinha P
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7925-7932. PubMed ID: 36869230
[TBL] [Abstract][Full Text] [Related]
17. Hypophysitis secondary to pembrolizumab: a case report and review of the literature.
Montero Pérez O; Sánchez Escudero L; Guzmán Ramos MI; Aviñó Tarazona V
Anticancer Drugs; 2022 Jan; 33(1):94-99. PubMed ID: 34261922
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review.
Fukuda I
J Nippon Med Sch; 2023 May; 90(2):149-156. PubMed ID: 36823122
[TBL] [Abstract][Full Text] [Related]
19. Silent, isolated ACTH deficiency in malignant melanoma patients treated with immune checkpoint inhibitors.
Heck A; Winge-Main AK
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34045201
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: a systematic review.
Wang F; Shi X; Yu X; Yang Y
Front Endocrinol (Lausanne); 2024; 15():1326684. PubMed ID: 38318292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
